Cargando…

Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy

INTRODUCTION: Immune checkpoint inhibitor (ICI)‐based treatment regimens have become the standard of care for first‐line treatment of metastatic epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) wild‐type non‐small cell lung cancer (NSCLC). Nevertheless, most patients inevitab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jia, Chen, Minjiang, Gao, Xiaoxing, Liu, Xiaoyan, Zhao, Jing, Pan, Ruili, Zhong, Wei, Xu, Yan, Wang, Mengzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008678/ https://www.ncbi.nlm.nih.gov/pubmed/36725772 http://dx.doi.org/10.1111/1759-7714.14806

Ejemplares similares

Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report
por: Taniguchi, Hirokazu, et al.
Publicado: (2021)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
por: Pons-Tostivint, E., et al.
Publicado: (2023)

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
por: Pons-Tostivint, E., et al.
Publicado: (2023)

Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam
por: Nguyen, Khanh Toan, et al.
Publicado: (2023)

The Three P's: Parotid, PD-L1, and Pembrolizumab
por: Wiggins, Amanda, et al.
Publicado: (2019)

Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
por: Wang, Simiao, et al.
Publicado: (2023)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
por: Que, Yi, et al.
Publicado: (2021)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
por: Zhou, Taotao, et al.
Publicado: (2022)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
por: Zhang, Jian-ye, et al.
Publicado: (2020)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report
por: Lyu, Mengmeng, et al.
Publicado: (2020)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
por: Mabbitt, Joseph, et al.
Publicado: (2023)

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
por: Yang, Hui, et al.
Publicado: (2020)

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
por: Yi, Ming, et al.
Publicado: (2022)

Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
por: Razaghi, Ali, et al.
Publicado: (2023)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
por: Giraldo, Nicolas A., et al.
Publicado: (2018)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Pembrolizumab Induces an Unexpected Conformational Change in the CC′-loop of PD-1
por: Roither, Bernhard, et al.
Publicado: (2020)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
por: Zhang, Yiru, et al.
Publicado: (2023)

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial
por: Blayney, Douglas W., et al.
Publicado: (2022)

Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma
por: Przystal, Justyna M., et al.
Publicado: (2021)

PK/PD integration of florfenicol alone and in combination with doxycycline against Riemerella anatipestifer
por: Zhang, Huilin, et al.
Publicado: (2022)

Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
por: Zhou, Qing, et al.
Publicado: (2023)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer
por: Chen, Minjiang, et al.
Publicado: (2021)

Synthesis, Characterization, and Magnetoresistive Properties of the Epitaxial Pd(0.96)Fe(0.04)/VN/Pd(0.92)Fe(0.08) Superconducting Spin-Valve Heterostructure
por: Yanilkin, Igor, et al.
Publicado: (2020)

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
por: Gong, Jun, et al.
Publicado: (2018)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020)

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
por: Sato, Hiro, et al.
Publicado: (2020)

A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
por: Kong, Xianbin, et al.
Publicado: (2021)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
por: Boustani, Jihane, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hohgtugca1tr4g14sarhabvtb9